Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedlenvatinib
Educational only, not medical advice. OncoForge makes no claim that Lenvatinib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
1
Preclinical
0
Other
0
1 studies1 review/other
Tracking 1 published study of Lenvatinib: 1 reviews/other.
Reported direction across studies: 1 mixed.
No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.
These counts summarize what the studies reported; they are not a measure of whether Lenvatinib works.
This review summarizes current knowledge on endometrial carcinosarcoma, an aggressive high-grade endometrial carcinoma with sarcomatous trans-differentiation that is often diagnosed at an advanced stage. It describes common molecular features (frequent p53 abnormalities; variable POLE/MSI-H) and current management: multimodal therapy with optimal surgery plus chemotherapy and radiotherapy, carboplatin/paclitaxel as first-line systemic therapy for recurrent/metastatic disease, and regulatory approvals for pembrolizumab plus lenvatinib in endometrial cancer generally. The authors note that carcinosarcoma patients were excluded from many immunotherapy trials and that emerging molecular insights may enable more personalized treatments in the future.
Studied with: carboplatin/paclitaxel doublet, pembrolizumab + lenvatinib, concomitant or sequential chemotherapy and radiotherapy, surgery plus chemotherapy and radiotherapy (multimodal).
Key findings
Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation.
Clinical presentation and diagnostic work-up are similar to endometrioid endometrial cancer, but carcinosarcoma is more frequently diagnosed at an advanced stage.
Endometrial carcinosarcoma encompasses different histological subtypes depending on the carcinomatous and sarcomatous elements.
The majority of endometrial carcinosarcomas are characterized by p53 abnormalities.
The proportion of POLE and microsatellite instability-high (MSI-H) is related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.
Non-metastatic disease management is multimodal with optimal surgery followed by concomitant or sequential chemotherapy and radiotherapy, even for early stages.
Palliative chemotherapy is recommended for metastatic or recurrent disease, with carboplatin/paclitaxel doublet as the first-line regimen.
Patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or combinations, although pembrolizumab and lenvatinib have FDA and EMA approvals in endometrial cancer after progression on chemotherapy (and single-agent immunotherapy in MSI-H cancers).
Emerging molecular knowledge is opening promising therapeutic options for more personalized treatment.
Limitations: This article is a narrative review rather than primary clinical trial data.; Endometrial carcinosarcoma is a rare and heterogeneous disease, limiting generalizable high-quality evidence.; Patients with carcinosarcoma were excluded from most immunotherapy studies, resulting in limited direct trial evidence for these agents in this histotype.; The abstract does not present new quantitative clinical trial outcomes specific to carcinosarcoma..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Lenvatinib's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.